{"id":"W2805363969","doi":"10.1200/jco.2018.36.18_suppl.lba1006","title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Clinical endpoint; Hazard ratio; Adverse effect; Oncology; Population; Randomized controlled trial; Cancer; Breast cancer; Placebo; Progression-free survival; Estrogen receptor; Confidence interval; Overall survival; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00124702,0.00150046,0.001519012,0.0003959798,0.0003371379,0.0008225086,0.001010405,0.001059666,0.004965354],"category_scores_gemma":[0.0006740913,0.0005670849,0.001227324,0.0004812633,0.0008439348,0.0006727108,0.0003274401,0.002274643,0.001092457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001378395,"about_ca_system_score_gemma":0.002167469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002864448,"about_ca_topic_score_gemma":0.007279605,"domain_scores_codex":[0.9997192,0.0001216885,0.0000117458,0.00004865986,0.0000249637,0.00007369483],"domain_scores_gemma":[0.9994018,0.0000783182,0.0001063038,0.00004752514,0.00003300495,0.0003330973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8655123,0.04183674,0.003267666,0.0005992003,0.001297404,0.0001084134,0.0001576726,0.002139479,0.0295981,0.0002522088,0.00424617,0.05098462],"study_design_scores_gemma":[0.740791,0.2464003,0.006888448,0.00002653465,0.000520169,0.0001222234,0.00004139216,0.0009161463,0.002411452,0.0001751377,0.001687165,0.00001993023],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872442,0.001706207,0.0007578021,0.0004161946,0.0001297885,0.004553053,0.002531723,0.0002090741,0.002451962],"genre_scores_gemma":[0.9825195,0.001523901,0.001973668,0.0008844542,0.000130813,0.00443649,0.004429926,0.00005273461,0.004048458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004965354,"threshold_uncertainty_score":0.0166108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03734654690843785,"score_gpt":0.4099493458190268,"score_spread":0.3726027989105889,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}